|
|
 |
CHEO Discovery Minute Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal disorders in which people have ulceration, inflammation, and bleeding of their gastrointestinal tract, and are at risk for complications in other parts of the body. People with IBD have an elevated risk of mental illness, especially anxiety and depression, potentially related to the inflammation in the gut affecting their brain. In this Discovery Minute, Dr. Eric Benchimol shares the results of a study where he and fellow researchers asked if women with IBD were at greater risk of developing a new mental illness during pregnancy and after giving birth compared to the overall population.
|
|
|
|
| Thursday, March 7, 2019 |
|
|
Dr. Jason Berman announced as new CEO and Scientific Director of CHEO RI and VP Research of CHEO
|
The following is a letter to partners from Alex Munter, CHEO’s President and CEO, and Caroline Somers, the Board Chair of the CHEO Research Institute
OTTAWA, March 7, 2019 - On behalf of the Boards of Directors of CHEO and the CHEO Research Institute (RI), we are pleased to share that Dr. Jason Berman will be the new CEO and Scientific Director of the CHEO RI and the VP Research of CHEO.
Dr. Berman joins us from Halifax’s IWK Health Centre and Dalhousie University, where he is the Interim Vice President Research, Innovation and Knowledge Translation, Associate Chair Research, Department of Pediatrics, and Full Professor in the Departments of Pediatrics, Pathology and Microbiology & Immunology at the Faculty of Medicine.
Read More
| |
| Thursday, February 28, 2019 |
|
|
CHEO bringing genetics to the front door with new Centre for Genomic Innovation
|
Centre will transform lives through rare disease diagnosis
OTTAWA, February 28, 2019 – On Rare Disease Day, CHEO’s new Centre for Genomic Innovation ran its first comprehensive clinical genomic test on site, marking a significant change in the diagnosis of rare diseases in Canada. With funding from the community through the CHEO Foundation, the Centre for Genomic Innovation will deliver genomic expertise as a front-line option of care for rare disease. World-renowned clinical geneticist at CHEO and senior scientist at the CHEO Research Institute, Dr. Kym Boycott, will be the new centre’s executive director.
Read More
| |
| Wednesday, February 20, 2019 |
|
|
Media Advisory: CHEO Researcher and Medical Geneticist Dr. Kym Boycott to appear at UN Rare Disease Day Policy Event
|
| OTTAWA February 20, 2019 – Dr. Kym Boycott, Medical Geneticist and Senior Scientist at CHEO and Professor of Pediatrics at the University of Ottawa, will be appearing at the United Nations Headquarters in New York on Thursday, February 21, 2019. She is presenting her world-renowned research and clinical work in genetics and rare disease as part of the Second High Level Event of the NGO Committee for Rare Disease. This is the first time CHEO has been represented at the UN.
Read More
| |
|